Abstracts S21 glucose compared to PCSK9+/+ littermates during the all period of HFD feeding. By contrast, PCSK9 deÀ ciency did not alter body weight, plasma triglyceride or free fatty acids levels in response to HFD. On regular diet, PCSK9-/-mice have signiÀ cant reduction of circulating cholesterol compared to PCSK9+/+ mice (0.721±0.05 g/l vs 1.06±0.04 P=0.0002). Surprisingly, after one week of diet, this phenotype was lost and cholesterol levels were not signiÀ cantly different between PCSK9-/-and PCSK9+/+ mice (respectively: 1.327±0.07 g/l vs 1.501±0.05 P=0.065).
Introduction -Proprotein convertase subtilisin kexin type 9 (PCSK9) is a natural inhibitor of the low density lipoprotein receptor (LDLR) and its deÀ ciency confers a high level of protection against cardiovascular disease. PCSK9 is well expressed in the liver and the intestine but its precise localization and its role in the digestive tract remain unknown.
Objectives -The aim of this study is to determine PCSK9 distribution and localization in the intestine and examine in mice whether it acts upon postprandial lipemia.
Methods & Results -In mice, we show that PCSK9 mRNA is highly expressed all along the small intestine and colon. Confocal microscopy on human intestines showed that PCSK9 is localized mainly in the enterocyte. Similar to hepatocytes, PCSK9 was induced by statins in polarized Caco-2 cells. Upon olive oil gavage, and in spite of similar fasting triglyceridemia, PCSK9-/-mice have a dramatically decreased postprandial triglyceridemia compared with their wild type littermates (WT) (0.075 g/L/h vs 0.2 g/L/h, p<0.01). Lymph analysis revealed that intestinal TG output is not quantitatively modiÀ ed by PCSK9 deletion. However, PCSK9-/mice present a signiÀ cant reduction of lymphatic apoB secretion compared to PCSK9+/+ mice. Modulating PCSK9 expression in polarized Caco-2 cells conÀ rmed the relationship between PCSK9 and apoB secretion ; PCSK9-/-mice consistently secrete larger TGrich lipoprotein than wild-type littermates. Finally, kinetic studies showed that PCSK9 deÀ cient mice have an increased ability to clear chylomicrons compared to wild-type littermates.
Conclusions -Altogether, these data suggest that PCSK9 deÀ ciency might protect against cardiovascular disease not only by affecting the LDLC but also by reducing postprandial triglyceridemia, an important risk factor.
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CARACTÉRISATION DES CELLULES ENDOTHÉLIALES DU TISSU ADIPEUX HUMAIN SOUS-CUTANÉ
A. VILLARET 1 , L. DANOUX 1 , C. JEANMAIRE 1 , G. PAULY 1 , M. LAFONTAN 2 , A. BOULOUMIE 2 1 Laboratoires Serobiologiques Cognis, Nancy, France 2 Inserm U858 I2MR, Toulouse, France Le tissu adipeux est un organe jouant un rôle majeur dans le maintien de l'homéostasie métabolique. De plus, la masse grasse a acquis le statut d'organe endocrine. EnÀ n, récemment, la présence de cellules du système immunitaire a été mise en évidence dans le tissu adipeux et suggérée comme étant responsable du développement de l'inÁ ammation chronique de bas niveau associée à l'obésité. Ces échanges de métabolites, d'hormones et de cellules entre compartiment adipeux et sanguin démontrent le rôle prépondérant de l'endothélium dans la masse grasse. Or, chez l'homme aucune étude n'a décrit l'endothélium du tissu adipeux. Cette étude a été menée aÀ n de caractériser le système capillaire du tissu adipeux humain sous-cutané abdominal et d'évaluer l'inÁ uence du degré d'adiposité des patients sur l'état d'activation des cellules endothéliales du tissu adipeux humain.
Nous avons déterminé, par observation in situ en immunoÁ uorescence que le tissu adipeux humain possédait un réseau capillaire très développé caractérisé par la double expression des marqueurs de surface CD31 et CD34. L'analyse en cytométrie en Á ux du nombre de cellules CD31+/CD34+ du tissu adipeux de patientes normopondérées (indice de masse corporelle (IMC) compris entre 20 et 25) et obèses (IMC supérieur à 30) a montré que le nombre de cellules CD31+/CD34+ est maintenu constant, démontrant que la croissance excessive du tissu adipeux s'accompagne d'une extension de son réseau capillaire. La caractérisation par PCR quantitative en temps réel de transcrits exprimés dans les cellules endothéliales capillaires CD31+/CD34+ du tissu adipeux humain isolées par une technique d'immunosélection/déplétion a mis en évidence un état d'activation inÁ ammatoire et angiogénique de ces cellules chez les sujets obèses. De plus, nous avons développé une technique de culture primaire de ces cellules permettant le maintien de l'expression des marqueurs endothéliaux.
En conclusion, cette étude a permis de mettre au point des techniques d'immunohistochimie en Á uorescence des réseaux capillaires du tissu adipeux humain et de culture primaire des cellules endothéliales. De plus, nos résultats montrent que le développement de la masse grasse chez l'homme module le phénotype des cellules endothéliales (activation inÁ ammatoire et angiogénique). Introduction -Un régime riche en acides gras de la série n-3 tel que l'acide docosahexaénoïque (DHA, 22 :6n-3) peut diminuer le risque d'accident cardiovasculaire en réduisant l'activation des plaquettes. Cependant de fortes doses de DHA peuvent favoriser l'induction de la peroxydation lipidique due au fort degré d'insaturation de cet acide gras et masquer partiellement voire contrebalancer les effets bénéÀ ques.
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EFFETS SUR LA FONCTION PLAQUETTAIRE ET LE STATUT REDOX D'UNE SUPPLEMENTATION EN ACIDE DOCOSAHEXAENOÏQUE CHEZ DES HOMMES SAINS
Objectifs -Notre objectif a été de déterminer l'effet du DHA sur la fonction plaquettaire et sur le stress oxydant chez des volontaires sains lorsque cet acide gras est ingéré à doses croissantes (200, 400, 800 et 1600 mg par jour sous forme de triglycérides, chaque dose pendant deux semaines). Background -A major complication of diabetes is the development of cardiac dysfunction in absence of vascular disease. Metabolic disorders such as insulin resistance (IR) and dyslipidemia (DL) might contribute to the induction of diabetic cardiomyopathy (DCM). However, few relevant animal models are currently available for studying the time-course of DCM and evaluating experimental therapeutics. We developed a rodent model of dietary-induced IR combined or not with DL in order to investigate the impact of chronic IR and DL on in vivo myocardial function.
Méthodes
Methods & Results -Male Sprague-Dawley rats were fed a westerntype diet (65 % fat ; 15 % fructose ; WD: n=12). DL was induced by combining the western diet with i.p. injections of a nonionic surfaceactive agent (P-407 ; 0.2 mg/kg, 3 times/wk ; WD-P407 n=9). A chow diet was used as control (Chow: n=9). At 6, 11 and 14 wks, cardiac function was assessed by echocardiography. After 6 wks, plasma insulin was signiÀ cantly increased in both WD and WD-P407 groups (P<0.05 vs. Chow). Fasting blood glucose increased in WD group while plasma lipids markedly accumulated in WD-P407-treated rats (P<0.05 and P<0.01 vs. Chow, respectively). Pulse-wave Doppler indicated impaired diastolic function at 14 wks (E/A wave ratio: WD-P407: 1.42±0.06 vs. Chow: 1.65±0.11). M-mode imaging showed no signiÀ cant differences in cardiac function and geometry under basal conditions. However, fractional shortening (FS) was signiÀ cantly depressed under dobutamine stress in WD group at 14 wks (FS in % of baseline: 151±9 % vs 196±7 % ; P<0.05) whereas systolic dysfunction appeared as early as 11 wks and worsened at 14 wks in WD-P407 animals (P<0.05 and P<0.01 vs. Chow, respectively). Finally, compared to Chow, myocardial lipid tissue content were signiÀ cantly higher in WD and WD-P407 groups, the cardiac lipid accumulation being more pronounced in the later. Introduction -A large body of experimental and clinical evidence indicates that some AT1 receptor antagonists may have beneÀ cial metabolic effects in addition to their well-known cardiovascular actions. Whether or not these metabolic effects are related to additional PPARγ agonist activity of some AT1 antagonists is still under debate. Therefore, the aim of the present study was to check the cardiovascular and metabolic effects of losartan lacking any PPAR agonist activity in a suitable experimental model of metabolic syndrome, namely SHHF rats (Spontaneously Hypertensive, Heart Failure). These rats exhibit obesity, hypertension, dyslipidemia and glucose intolerance. They lack leptin receptors. WKY and SH rats were considered as control of SHHF rats.
Conclusions
Methods -Losartan was delivered in the drinking water (10 mg/ kg/day during 3 months) to 12-week-old male rats. Cardiovascular and metabolic parameters were measured at the end of the treatment and compared to those of untreated SHHF rats at the same age. Intravenous glucose tolerance tests (IVGTT) were also performed. Total cholesterol, LDL, HDL, triglycerides and glucose were measured on plasma samples (0,5 ml) taken from caudal veins. Blood pressure was measured (right femoral artery) under pentobarbital anaesthesia (60 mg/kg, ip).
